Pre-operative neoadjuvant chemotherapy cycles and survival in newly diagnosed ovarian cancer: what is the optimal number? A Memorial Sloan Kettering Cancer Center Team Ovary study

Ying L Liu; Qin C Zhou; Alexia Iasonos; Dennis S Chi; Oliver Zivanovic; Yukio Sonoda; Ginger Gardner; Vance Broach; Roisin O'Cearbhaill; Jason A Konner; Rachel Grisham; Carol A Aghajanian; Nadeem R Abu-Rustum; William Tew; Kara Long Roche

doi:10.1136/ijgc-2020-001641

Citation Tools

other Versions

You are currently viewing an earlier version of this article (December 08, 2020).
View the most recent version of this article

Original research

Pre-operative neoadjuvant chemotherapy cycles and survival in newly diagnosed ovarian cancer: what is the optimal number? A Memorial Sloan Kettering Cancer Center Team Ovary study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Cite this article as:: Liu YL, Zhou QC, Iasonos A, et al

Pre-operative neoadjuvant chemotherapy cycles and survival in newly diagnosed ovarian cancer: what is the optimal number? A Memorial Sloan Kettering Cancer Center Team Ovary study

International Journal of Gynecologic Cancer Published Online First: 26 October 2020. doi: 10.1136/ijgc-2020-001641

Log in using your username and password

Main menu

Log in using your username and password

You are here

other Versions

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password